Tetsu Hirakawa

Dr. Tetsu Hirakawa

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
THTetsu Hirakawa
Tetsu Hirakawa
KYKakuhiro Yamaguchi
Kakuhiro Yamaguchi
KFKunihiko Funaishi
Kunihiko Funaishi
KSKiyofumi Shimoji
Kiyofumi Shimoji
SSShinjiro Sakamoto
Shinjiro Sakamoto
NHNoboru Hattori
Noboru Hattori
Background/Objectives: Vascular endothelial growth factor (VEGF)-A promotes an immunosuppressive tumor microenvironment, potentially affecting the efficacy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody therapy. VEGF121 and VEGF165, VEGF-A isoforms, promote and inhibit tumor growth, respectively. Additionally, VEGF-A levels differ depending on whether they are measured in serum or plasma. However, whether the serum or plasma levels of total VEGF-A (tVEGF-A) or its isoforms are the most suitable for predicting anti-PD-1/PD-L1 antibody therapy efficacy remains unclear. Methods: Eighty-six patients with non-small-cell lung cancer (NSCLC) who were treated with anti-PD-1/PD-L1 antibody monotherapy between December 2015 and December 2023 were retrospectively enrolled. The association between the serum and plasma levels of tVEGF-A and its isoforms (VEGF121 and VEGF165) and treatment outcomes was analyzed. Results: The median progression-free survival (PFS) was 2.9 months, and the objective response rate (ORR) was 23.3%. PFS was significantly shorter in patients with higher tVEGF-A serum levels (≥484.2 pg/mL) than in those without (median PFS 2.1 vs. 3.7 months, p = 0.004). In contrast, plasma tVEGF-A levels could not be used to stratify PFS. Therefore, the serum levels of VEGF-A isoforms were measured. Patients with higher VEGF121 serum levels (≥523.5 pg/mL) showed both significantly shorter PFS (median PFS 2.3 vs. 3.3 months, p = 0.022) and a lower ORR (9.7% vs. 30.9%, p = 0.033) than those without. Multivariate Cox and logistic regression analyses showed that higher levels of serum VEGF121 were significantly associated with shorter PFS and a lower ORR. Conclusions: Serum VEGF121 levels may be useful in predicting anti-PD-1/PD-L1 antibody monotherapy efficacy.

5 July 2025 in European Journal of Cancer
Verified
Journal Article
Open access
KYKakuhiro Yamaguchi
Kakuhiro Yamaguchi
STShun Takao
Shun Takao
NKNobuhiro Kanaji
Nobuhiro Kanaji
THTetsu Hirakawa
Tetsu Hirakawa
NMNaoko Matsumoto
Naoko Matsumoto
NHNoboru Hattori
Noboru Hattori
Checkpoint inhibitor pneumonitis (CIP), especially graded as 3-5 or developed within 6-12 weeks, worsens the prognosis of patients with cancer. However, a risk assessment method for the disease has not been established. This was a prospective study that aimed to identify a blood biomarker to assess a risk of severe CIP. This multicenter prospective study enrolled patients with non-small cell lung cancer who were treated with anti-PD-1/PD-L1 antibodies in the first-line therapy. The potential of high mobility group box 1 (HMGB1) for Grade 3-5 CIP developed within 3 months after the first administration of anti-PD-1/PD-L1 antibody (CIPG3-5/3months) was evaluated in the discovery cohort (December 2021-November 2022) and validation cohort (December 2022-November 2023). In the discovery and validation cohorts, 8.2 % and 6.2 % of patients experienced CIPG3-5/3months, respectively. The HMGB1 cut-off level was set at 8.1 ng/mL by receiver operating characteristic analysis in the discovery cohort (AUC = 0.732), yielding 80.0 % sensitivity and 71.1 % specificity in the validation cohort. The incidence rate of CIPG3-5/3months was significantly higher in patients with high HMGB1 level than in those without, both in the discovery cohort (18.2 % and 2.6 %, respectively; P = 0.028) and validation cohort (15.4 % and 1.8 %, respectively; P = 0.035). The potential of HMGB1 for assessing the risk was specific for CIP because HMGB1 serum levels were not elevated in patients with immune related adverse events other than CIP. HMGB1 can be a serum biomarker that specifically assesses the risk of severe CIP.

4 June 2026 in Respirology
Verified
Journal Article
Open access
PDF file
THTetsu Hirakawa
Tetsu Hirakawa
KYKakuhiro Yamaguchi
Kakuhiro Yamaguchi
STShun Takao
Shun Takao
NKNobuhiro Kanaji
Nobuhiro Kanaji
NMNaoko Matsumoto
Naoko Matsumoto
NHNoboru Hattori
Noboru Hattori
Background and Objective: Severe checkpoint inhibitor pneumonitis (CIP), particularly when it develops within 6–12 weeks, is a potentially fatal adverse event in patients with non‐small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). Although neutrophil‐to‐lymphocyte ratio (NLR) has been reported to predict immune‐related adverse events, its role in severe CIP remains unclear. Methods: The discovery cohort retrospectively enrolled 102 patients with NSCLC treated with ICI monotherapy at Hiroshima University Hospital. The validation cohort prospectively enrolled 191 NSCLC patients receiving first‐line treatment, including ICI, at 15 institutions. Severe CIP was defined as grade 3–5 pneumonitis occurring within 3 months of treatment initiation. The cut‐off level of the baseline NLR was identified by receiver operating characteristic curve analysis in the discovery cohort, and the predictive accuracy was analyzed and confirmed in both cohorts. Results: Severe CIP was observed in seven (6.9%) and 11 (5.8%) patients in the discovery and validation cohorts, respectively. In the discovery cohort, the baseline NLR was higher in patients with severe CIP than in those without (17.29 [4.76–20.73] vs. 3.70 [2.64–6.68], p = 0.006), and the cut‐off level of the baseline NLR was set at 4.75 (AUC 0.81; sensitivity 85.7%, specificity 64.2%). The incidence of severe CIP was significantly higher in patients with higher baseline NLR levels (≥ 4.75) than in those without, in both cohorts (discovery: 15.0% vs. 1.6%, p = 0.009; validation: 10.3% vs. 3.3%, p = 0.046). Conclusion: Baseline NLR is a promising risk stratification marker for severe CIP.

9 June 2026 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
THTetsu Hirakawa
Tetsu Hirakawa
KYKakuhiro Yamaguchi
Kakuhiro Yamaguchi
KSKiyofumi Shimoji
Kiyofumi Shimoji
SSShinjiro Sakamoto
Shinjiro Sakamoto
YHYasushi Horimasu
Yasushi Horimasu
NHNoboru Hattori
Noboru Hattori
Background: Vascular endothelial growth factor (VEGF)-A, which is overexpressed in epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC), has been implicated in resistance to EGFR-tyrosine kinase inhibitors (TKIs). VEGF-A comprises several isoforms, including VEGF 121 and VEGF 165 . However, the clinical potential as blood biomarkers in EGFR-TKI treatment remains unclear. Methods: We retrospectively analyzed 64 patients with advanced EGFR -mutated NSCLC who received EGFR-TKI monotherapy at Hiroshima University Hospital between November 2009 and August 2023. Pre-treatment serum levels of total VEGF-A (tVEGF-A), VEGF 121 , and VEGF 165 were measured using enzyme-linked immunosorbent assays. The association of these biomarkers with the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was analyzed. Results: The ORR was 78.1%, and the median PFS and OS were 7.5 and 31.8 months, respectively. Serum VEGF 121 levels were significantly higher in non-responders than in responders (median, 446.6 vs. 322.1 pg/mL, p = 0.043), whereas no significant differences were observed for tVEGF-A and VEGF 165 levels. Receiver operating characteristic analysis identified an optimal serum VEGF 121 cut-off level of 339.3 pg/mL (AUC: 0.678, sensitivity: 52.0%, specificity: 92.9%). Patients with higher serum VEGF 121 (> 339.3 pg/mL) had significantly lower ORR (64.9% vs. 96.3%, p = 0.003), shorter PFS (median, 6.2 vs. 14.4 months, p = 0.026), and shorter OS (median, 27.6 months vs. not reached, p = 0.040) than those with lower serum VEGF 121 (≤ 339.3 pg/mL). Conclusion: Higher levels of serum VEGF 121 were associated with lower EGFR-TKI efficacy and poorer prognosis in patients with EGFR -mutated NSCLC.

10 June 2026 in Cureus
Verified
Journal Article
Open access
IOIkuko Ooka
Ikuko Ooka
THTetsu Hirakawa
Tetsu Hirakawa
YTYoshito Temma
Yoshito Temma
TYTetsuji Yamaguchi
Tetsuji Yamaguchi
TITomokazu Ishitobi
Tomokazu Ishitobi
A 76-year-old woman with a history of polymyalgia rheumatica, dyslipidemia, and osteoporosis was admitted due to a one-week history of productive cough and was initially diagnosed with bacterial pneumonia. Despite antibiotic therapy, her clinical condition worsened, leading to respiratory failure. Further history-taking revealed that she had been taking kakkonto, a Japanese herbal medicine (JHM), for the preceding 4.5 months as a self-initiated measure to prevent infection. The patient was eventually diagnosed with kakkonto-induced pneumonitis. Kakkonto was discontinued, and systemic corticosteroid therapy was initiated, resulting in rapid improvement. The peripheral blood drug-induced lymphocyte stimulation test was positive for kakkonto. Because the clinical and radiological findings of JHM-induced pneumonitis are nonspecific, careful medication history-taking, particularly for JHM, is essential for diagnosing unexplained pneumonitis.

6 July 2026 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
THTetsu Hirakawa
Tetsu Hirakawa
KYKakuhiro Yamaguchi
Kakuhiro Yamaguchi
KSKiyofumi Shimoji
Kiyofumi Shimoji
SSShinjiro Sakamoto
Shinjiro Sakamoto
YHYasushi Horimasu
Yasushi Horimasu
NHNoboru Hattori
Noboru Hattori